Search results
Results from the WOW.Com Content Network
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
And since it split from Abbott in 2013, AbbVie has increased its dividend by 310%. The stock's forward yield is now around 3.8%, compared to the S&P 500's average of 1.3%. So despite its recent ...
Amgen (NASDAQ: AMGN) offers an intriguing test case for this dynamic heading into 2025. ... a key driver of the biotech stock's strong performance earlier in the year. Specifically, the company's ...
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact. Let's find out what ...
In a reverse stock split, your current shares are exchanged for fewer shares. When the split occurs, the share price also changes automatically to reflect the exchange ratio. That is, regardless ...
While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to ...
AMGN stock is down roughly 2.5% after the bell following the company's strong quarterly earnings results, but weak first-quarter guidance. Shares had been rising slightly in anticipation of Amgen ...